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Abstract: 
1H  NMR  spectroscopy  of  urine  has  been  applied  to  exploring  metabolomic 
differences  between  people  diagnosed  with  Balkan  endemic  nephropathy  (BEN),  and 
treated by haemodialysis, and those without overt renal disease in Romania and Bulgaria. 
Convenience sampling was made from patients receiving haemodialysis in hospital and 
healthy controls in their village. Principal component analysis clustered healthy controls 
from both countries together. Bulgarian BEN patients clustered separately from controls, 
though in the same space. However, Romanian BEN patients not only also clustered away 
from controls but also clustered separately from the BEN patients in Bulgaria. Notably, the 
urinary metabolomic data of two people sampled as Romanian controls clustered within the 
Romanian BEN group. One of these had been suspected of incipient symptoms of BEN at 
the time of selection as a ‗healthy‘ control. This implies, at first sight, that metabolomic 
analysis  can  be  predictive  of  impending  morbidity  before  conventional  criteria  can 
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diagnose  BEN.  Separate  clustering of BEN patients from  Romania  and Bulgaria  could 
indicate difference in aetiology of this particular silent renal atrophy in different geographic 
foci across the Balkans. 
Keywords: Balkan nephropathy; metabolomics; urinalysis; haemodialysis; ochratoxin A; 
aristolochic acid 
 
1. Introduction  
The Balkan endemic nephropathy was first recognised in the mid 1950s as a slow, progressive and 
silent morbidity in certain rural communities in Bulgaria, the former Yugoslavia and Romania [1–5]. It 
is characterised by gradual deterioration of urinary excretion, and is confirmed post-mortem by the 
profound atrophy of both kidneys. An increased incidence of tumours of the urinary tract is associated 
with the nephropathy, but this does not include renal cell carcinoma. Many studies have since sought to 
discover the cause of this uremic disease, with many theories passing in and out of favour, but there 
seems still no satisfactory identification of the causal factor(s). Marked histopathological changes have 
already  occurred  by  the  time  the  morbidity  is  diagnosed  and  therefore  the  course  of  early  stages 
remains unclear. Particularly there are no biomarkers specific to the very early stage of disease.  
Development  of  metabolomics,  from  the  early  discovery  of  the  analytical  power  of 
1H  NMR 
spectroscopy  of  small  volumes  of  human  and  experimental  animal  blood  and  urine  [6,7],  offers 
potential  for  recognition  of  disorder  by  combinations  of  biomarkers.  Combining  the  advantage  of 
several years of involvement with the disease with opportunity to apply for the first time the new field 
of metabolomics, an informal international collaboration was established in 2003 to explore urine of 
Balkan  nephropathy  patients  and  of  apparently  health  control  subjects  in  regions  of  Bulgaria  and 
Romania where the nephropathy has been and remains hyperendemic.  
2. Materials and Methods 
2.1. Romania: Balkan Nephropathy 
Urine of 21 BEN patients was collected at the Dialysis Center in Drobeta Turnu Severin during 
attendance for routine haemodialysis in May 2003 (15 subjects) or as the second urination of the day 
after overnight stay in hospital (6 subjects). The samples were representative of a typical routine day at 
that  clinic.  All  urine  samples  were  collected  into  15  mL  calibrated  Falcon  tubes  containing  
1 mL 1% sodium azide solution.  
Four additional samples were obtained from the same hospital in 2004; two samples came from 
females which provided samples 12 and 18 in the 2003 group, and one of these was currently receiving 
peritoneal dialysis (Supplementary Table 4). The other two were additions to the study which was 
therefore conducted on 25 urine samples (M:F ratio 10:15) from 24 separate BEN subjects. One sample 
came from a patient who had been admitted to hospital during the night following a home visit from 
several of us. None of the persons was suspected of having a urinary tract tumour. Toxins 2011, 3                               
 
817 
2.2. Romania: Control 
Control samples (18) were obtained a year later (21–22 April 2004), partly (13 subjects) in the 
historically (since 1957)-hyperendemic nephropathy village of Erghevita where residents had become 
accustomed over many years to medico-scientific visits concerning BEN. Subjects were selected as 
convenient, arising voluntarily from casual informal interaction with residents during the visit. Five 
samples were also taken from a family adjacent to a BEN-family in a nearby village. Age and general 
features of health were noted during private conversation with one of us (D.T., who is a medical 
doctor). Thus we ensured that only persons without any history of nephropathy, and not currently 
taking prescribed medication, were asked to provide a sample. All conversants were co-operative, since 
this did not require any invasive procedure. Sample composition was therefore conditioned mainly 
according to fluid intake during the first half of the day; samples from Erghevita are mostly listed 
(Supplementary Table 3) in chronological order of collection. For example, sample 6 was collected at 
10 a.m., samples 7 and 8 around 11 a.m., samples 9 and 10 at mid-day (subjects had recently consumed 
beer), samples 12–16 during early afternoon, samples 11,17,18 later in afternoon. Samples (~10 mL) 
were immediately mixed with 1 % sodium azide solution (1 mL) as above. 
Whereas, for obtaining the nephropathy samples the subjects were self-selected according to visiting 
the hospital for haemodialysis, subjects for the control samples were also self-selected by availability 
in routine village life, including typical consumption of beer by some residents on a hot day. Notably, 
however, after informal ―consultation‖ with one person in Erghevita, D.T. spontaneously expressed the 
clinical opinion that that person could already unwittingly be showing clinical signs of BEN. None of 
the persons was suspected of having a urinary tract tumour. 
2.3. Bulgaria: Balkan Nephropathy and Controls 
Groups of samples from BEN patients (case 19, Supplementary Table 2), receiving haemodialysis, 
and  apparently  healthy  controls  (case  21,  Supplementary  Table  1)  were  obtained  from  females  in 
endemic villages in the Vratza region from the second urination of the day after overnight fast. Freshly 
collected urine (5–10 mL) was added to 1 mL 1% sodium azide solution as preservative in a graduated 
plastic tube. None of the persons was suspected of having a urinary tract tumour. 
2.4. Romania: Patients with Urological Disease not Associated with BEN 
Since  there  was  no  overt  evidence  of  urinary  tract  tumours  developing  in  any  of  the  subjects 
sampled in the categories above, urine samples were collected according to the protocol above at the 
County  Hospital,  Timisoara  in  October  2003  from  seven  local  residents  with  urological  disease 
requiring surgery. Timisoara is ~200 Km north-west of the nephropathy area and the subjects had no 
diagnosis involving BEN. The samples were collected during days prior to the surgical procedure and 
served as disease-controls in relation to the samples collected from BEN patients in 2.1 above. Samples 
were from six males and one female (age range 58–75 years) with tumours in prostate, kidney, bladder, 
upper urinary tract and periuretral tissues. Toxins 2011, 3                               
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2.5. Urinalysis 
Urinalysis for creatinine, calcium, urate, protein, sodium, potassium, phosphate and urea was made 
by standard automated methodology [8] in the Chemical Pathology Department at St Mary‘s Hospital, 
London. Data adjustment was made according to the urine dilution effected by the azide preservative. 
It  was  not  possible  to  know  whether  any  creatinine  concentration  values  varied  atypically  due  to 
excessive  or  limited  recent  consumption  of  liquid,  but concentration  values for all other analysed 
parameters  in  each  sample  were  adjusted  relative  to  1  mmol  creatinine,  to  allow  comparability  
across samples. 
2.6. 
1H NMR Spectroscopic Analysis of Urine 
Each  sample  (400µ L)  was  mixed  with  200  µL  of  phosphate  buffer  (0.2  M  NaH2PO4:  
0.2 M Na2HPO4 (19:81), pH 7.4). Aliquots of the resulting mixture (500 mL) were placed in 5 mm 
NMR tubes to which 50 mL of a solution of TSP in D2O was added (final concentration, 1 mM). The 
D2O plus TSP addition provided both a chemical shift reference (δ 0.0) and a field frequency lock 
signal. One-dimensional (1D) 
1H NMR spectra were acquired at 699.93 MHz on a Bruker Avance  
700 spectrometer using a standard pre-saturation pulse sequence for water suppression with solvent 
irradiation in the relaxation delay (3 s) and the mixing time (100 ms). NMR spectra were acquired 
using 128 scans into 64 k points with a spectral width of 14097 Hz, an acquisition time of 2.32 s, and a 
total pulse recycle delay of 5.42 s. The FIDs were multiplied by an exponential function corresponding 
to  a  0.3  Hz  line  broadening  prior  to  Fourier  transformation.  All  data  were  phased  and  baseline 
corrected manually in TopSpin (version 2.5, Bruker GmbH, Germany).  
2.7. Multivariate Statistical Analysis of 1H NMR Spectral Data 
All NMR spectra were processed for multivariate statistical analysis using the AMIX software 
(version  3.9.7,  Bruker  GmbH,  Germany).  The  spectra  were  normalised  to  the  total  integral 
(excluding water, urea and TSP) and data reduced to a series of 0.02 ppm integrated regions for 
analysis.  The  reduced  dataset  was  pre-processed  (pareto  scaling)  and  analysed  via  Principal 
Component Analysis (PCA) and Partial Least Squares–Discriminant Analysis (PLS-DA) using the 
SIMCA−P+ software package (version 11.5, Umetrics, Umea, Sweden). Comparisons were made 
between the data from the two groups of control subjects and the two groups of subjects diagnosed 
with Balkan Endemic Nephropathy (BEN). Those regions of the NMR spectra causing clustering in 
the data were identified from the coefficients. The metabolites were assigned based on comparison 
to authentic standards, existing data and on-line resources.  
3. Results 
Analysis  of  several  standard  urinary  parameters  indicative  of  renal  function,  particularly  when 
expressed relative to a unitary value of creatinine concentration, defined the status of each subject 
concerning the urine sample studied also by 
1H NMR spectroscopy. Table 1 summarises the analytical 
findings;  the  detail  can  be  seen  in  Tables  1–5  in  Supplementary  data.  Considerable  variation  in 
creatinine concentration in controls from both Balkan countries and elsewhere is normal for human Toxins 2011, 3                               
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populations. An important factor is the extent of liquid intake in the preceding few hours. Therefore the 
rather  similar  distribution  ranges,  expressed  both  in  the  present  apparently  healthy  controls 
(Supplementary Tables 1 and 3), and in the BEN subjects just before receiving one of the thrice-weekly 
sessions of haemodialysis (Supplementary Tables 2 and 4), confirms the value of the former as controls 
and indicates the general success of haemodialysis in sustaining adequate renal function in spite of a 
diagnosis of BEN. However, the range of population values for creatinine concentration, as directly 
measured for control and BEN groups, distinguished control and BEN groups in each country by the 
dominance of diluted urine in most of the BEN subjects (Figure 1). The three lowest values for the 
Romanian controls were from subjects who had recently been drinking. Four additional BEN samples 
collected in 2004 (in the range 2–6 mmol/L) conformed to the pattern for 2003.  
Table  1. Urinalysis data summarised from detail shown in Tables 1–5 (Supplementary 
data). Mean values (±  SD) for Bulgarian and Romanian control and BEN groups, and a 
group of non-BEN subjects with urinary tract tumours. Units: creatinine (mmol/L), and 
other parameters (mmol/mmol creatinine). 
    Creatinine  Calcium  Urate  Protein  Sodium  Potassium  Phosphate  Urea 
Bulgaria  Control  13.1(7.9)  0.14(0.1)  0.25(0.09)  13.1(7.9)  18.9(8.3)  4.9(3.5)  1.4(0.8)  23.4(8.7) 
  BEN  8.8(5.8)  0.24(0.18)  0.2(0.18)  8.8(5.8)  30.0(15.7)  6.2(2.0)  2.6(1.4)  40.3(11.1) 
Romania  Control  6.4(3.8)  0.26(0.24)  0.29(0.14)  6.4(3.8)  28.1(13.2)  5.8(2.6)  4.3(4.5)  32.0(12.7) 
  BEN  4.4(2.5)  0.14(0.1)  0.2(0.08)  4.4(2.5)  34.6(21.2)  3.8(1.8)  1.8(1.4)  21.2(6.7) 
  Non-BEN 
UTT 
11.3(4.2)  0.37(0.37)  0.23(0.1)  11.3(4.2)  19.2(8.4)  2.9(0.6)  2.3(0.9)  46.1(15.6) 
Data  from  all  NMR  spectra  were  assessed  visually  to  confirm  data  quantity  follow ing  NMR 
processing, and then explored using multivariate statistical analysis. The initial stage of data analysis 
included an assessment of those samples found to be strong outliers from the majority of the urinary 
data. One set of outliers was found to be due to the presence of very high concentrations of ethanol in 
the samples. This was presumed to be due to alcohol consumption by the subject since no other sources 
were identified in the collection or analysis stages. Due to the potential for other physiological effects 
from such consumption, the subject was excluded from the analysis. Similarly, those subjects that 
showed abnormally high levels of glucose in their urine, without the presence of other metabolites to 
imply a nephrotoxic event, were considered to be undiagnosed or undeclared diabetes sufferers and 
were also excluded from the analyses. Further to the exclusion of subjects, signals were observed in the 
NMR data to imply the presence of paracetamol (acetaminophen). Such background and undeclared  
use of non-steroidal anti-inflammatory drugs is commonly found in clinical metabolomic assessments. 
The level of paracetamol signals observed did not imply the sustained use of the drug and, rather than 
exclude  the subjects, those regions of the NMR spect ra assigned to the paracetamol signals were 
excluded from analysis. Furthermore, the regions accounting for the creatinine signals were also 
excluded since, even with pre-processing, these signals dominated the analysis, thereby obscuring other 
metabolic alterations.  Toxins 2011, 3                               
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Figure 1. Comparisons of urinary creatinine concentrations in sample groups sourced in 
Bulgaria  and  Romania  showing  dominance  of  lower  values  for  people  diagnosed  with 
BEN. Illustration of Bulgarian data omitted one exceptionally high value (42.5 mmol/L) for 
a control subject, which otherwise distorts the graphical format. The three lowest values for 
the Romanian controls were from subjects who had recently been drinking. 
 
An initial PCA assessment of the data was made comparing the samples from the control and BEN 
subjects  from  both  Romania and Bulgaria along with samples from Romanians with other kidney 
related disease. The scores from the data showed that the majority of the samples from Romanian BEN 
patients separated from the samples from all other groups. However, this separation dominated the 
analysis and all other groups mapped in the same scores space. PCA examination of the data without 
the Romanian BEN subjects resulted in all groups mapping together in scores space. From examination 
of the loadings it was apparent that a high degree of variation existed across the samples, which was 
not representative of any group structure. Some baseline distortion was noted along with some samples 
showing  a  dominance  of  the  scores  space.  Rather  than  exclude  these  moderate  outliers,  it  was 
considered more informative to apply a correlation based analysis. 
PLS-DA analysis of the data from all groups resulted in observation similar to the PCA, with the 
Romanian BEN subjects separating from the other groups (Figure 2). 
When viewed as the plot of the first and second components, one of the samples from the Bulgarian 
BEN  group  was also  observed  to  map with the Romanian BEN samples.  Three of the Romanian 
Control  samples  also  showed  a  trend  towards  this  space.  This  would  infer  that  the  three  control 
Romanians would be showing some metabolic characteristics of BEN, yet had not, at the time of 
sampling, been clinically diagnosed. The variation in the BEN group was sufficiently great that it 
dominated the first component. From the coefficients calculated from each variable, those regions of 
the  NMR  spectrum  of  greatest  influence  to  this  separation  of  the  Romanian  BEN  group, and the 
endogenous metabolites they represented, were identified.  Toxins 2011, 3                               
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Figure  2. PLS-DA scores plot of the urinary data from Romanian and Bulgarian BEN 
patients, familial/regional control subjects and subjects with other forms of kidney disease. 
 
The separation of the samples from the Romanian BEN group was caused by a urinary increase in 
glucose, lactate, trimethylamine N-oxide (TMAO) and acetate. The region δ 0.75–1.05 was observed to 
be increased in the samples from the BEN patients but, due to the extensive overlap of resonances, 
precise assignment could not be achieved. Typical urine data would contain signals from amino acids, 
small organic acids and, potentially, protein in this region of the NMR spectrum. Increase to any of these 
groups would be expected to occur in cases of kidney damage. These changes reflected the general 
pathophysiological alterations associated with nephrotoxicity or kidney disease. Further to these general 
alterations,  selected  metabolites  were  noted  that  may  be  more  implicated  either  as  cause  or  effect  
of the BEN observed. These included an increase in myo-inositol (δ 4.06, 3.63, 3.55, 3.26) and choline  
(δ 4.06, 3.55, 3.21). A number of other resonances were noted to be elevated in the samples from the 
Romanian  BEN  subjects,  but  there  was  insufficient  information  for  assignment.  The  metabolites, 
recognised from NMR signals, in these comparisons are listed in Tables 2–5. In comparison, a reduction 
in  the  concentration  of  a  number  of  urinary  components  was  observed,  including  creatine, 
phosphocreatine, pyruvate, dimethylglycine, citrate, glycine, succinate, formate and trigonelline. Toxins 2011, 3                               
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Table 2. Mean fold change and p values for metabolites identified to change in urine samples 
from Romanian BEN subjects compared to samples from Romanian Control subjects. 
Metabolite  Mean Fold  p  Variation 
Protein, amino, organic acids  1.80  4.47 ×  10
−6  elevated 
Lactate  1.47  8.30 ×  10
−2  elevated 
Unknown triplet  1.57  6.61 ×  10
−4  elevated 
Glucose  1.83  1.56 ×  10
−4  elevated 
Myo-inositol  1.76  1.27 ×  10
−4  elevated 
3-hydroxyisovalerate  1.39  8.88 ×  10
−4  reduced 
Pyruvate  1.51  1.67 ×  10
−5  reduced 
Citrate  1.93  4.38 ×  10
−4  reduced 
Dimethylamine  1.44  7.05 ×  10
−5  reduced 
Trimethylamine  1.77  9.40 ×  10
−7  reduced 
Dimethylglycine  1.71  7.59 ×  10
−5  reduced 
Taurine  1.46  1.31 ×  10
−3  reduced 
Glycine  1.28  2.29 ×  10
−2  reduced 
Creatine  1.78  1.70 ×  10
−6  reduced 
Phosphocreatine  1.49  3.34 ×  10
−3  reduced 
Formate  2.47  1.05 ×  10
−2  reduced 
Trigonelline  1.99  2.49 ×  10
−4  reduced 
Table 3. Mean fold change and p values for metabolites identified to change in urine samples 
from Bulgarian BEN subjects compared to samples from Bulgarian Control subjects. 
Metabolite  Mean Fold  p  Variation 
Lactate  1.43  5.93 ×  10
−3  elevated 
Citrulline  1.49  7.36 ×  10
−3  elevated 
Choline  1.45  2.85 ×  10
−2  elevated 
TMAO  2.29  2.89 ×  10
−4  elevated 
Citrate  0.67  1.66 ×  10
−1  reduced 
Succinate  0.88  8.88 ×  10
−2  reduced 
TMA  1.00  3.38 ×  10
−1  reduced 
Glycerophosphocholine  0.99  4.92 ×  10
−1  reduced 
Table 4. Mean fold change and p values for metabolites identified to change in urine samples 
from Romanian Control subjects compared to samples from Bulgarian Control subjects. 
Metabolite  Mean Fold  p  Variation 
Citrate  1.22  1.90 ×  10
−1  elevated 
TMA  1.00  2.20 ×  10
−1  elevated 
Glycerophosphocholine  0.985472668  0.454055919  elevated 
Phenylacetic acid  1.41  1.96 ×  10
−2  elevated 
Lactate  1.42  4.92 ×  10
−2  Reduced 
Dimethylglycine  1.692875166  0.006970254  Reduced 
Choline  1.537199456  0.005899252  Reduced 
TMAO  1.588133198  0.009447084  Reduced 
Glycine  1.259082095  0.061166452  Reduced 
Phosphocreatine  1.559161391  0.003522414  Reduced 
Trigonelline  2.193825386  0.001786463  Reduced 
Hippurate  1.53  8.45 ×  10
−2  Reduced Toxins 2011, 3                               
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Table  5. Mean fold change and p values for metabolites identified to change in urine 
samples from Bulgarian BEN subjects compared to samples from Romanian BEN subjects. 
Metabolite  Mean Fold  p  Variation 
Lactate  1.52  7.27 ×  10
−3  Elevated 
Acetate  1.36  1.36 ×  10
−1  Elevated 
Glucose  1.70  1.49 ×  10
−4  Elevated 
Myo-inositol  1.23  4.80 ×  10
−3  Elevated 
TMAO  1.28  1.68 ×  10
−1  Elevated 
Protein, amino acids and organic acids  1.86  1.50 ×  10
−6  elevated 
Citrate  1.80  5.81 ×  10
−3  Reduced 
Pyruvate  1.61  2.47 ×  10
−7  Reduced 
Taurine  1.85  1.44 ×  10
−4  Reduced 
Glycine  1.45  1.92 ×  10
−8  Reduced 
Phosphocreatine  1.22  8.26 ×  10
−3  Reduced 
Although the separation of the Romanian BEN sufferers represented the greatest variation in the 
data, sufficient variability existed in the data for the samples from the control and Bulgarian BEN 
patients to merit examination of the sources of this difference. Figure 4 shows the plot of the second 
and third components, with the data for the samples from the Romanian BEN patients hidden for 
clarity. Sufficient variation existed between the groups to give rise to the mapping of the groups in 
three clearly identifiable regions of the plot. The data indicated that, based on this small set of data, 
urinary variation enabled identification of the country of origin of the subject providing the sample. 
From the 3D scores plot in Figure 2 and the data shown in the 2D scores plots (Figures 3 and 4), it 
was  apparent  that  the  variation  in  the  data  giving  rise  to  the  separation  of  the  samples  from  the 
Romanian BEN subjects was not reflected in the samples from the other subjects. From examination of 
the  NMR  spectral  data  and  comparison  to  available  on-line  metabolic  profiling  data  sources  the 
following observations were made. Many of the observations reflected those seen between the samples 
from Romanian BEN subjects and the Romanian control subjects. The urinary alterations included an 
increase relative to the samples from Bulgarian BEN subjects in acetate, lactate, glycine, myo-inositol, 
indolelactate  (tentative),  and  glucose  along  with  an  increase  to  the  region  δ  0.90–1.00  typically 
attributed to amino acids (e.g., isoleucine), short chain organic acids and protein. A higher level of 
metabolites was observed in the samples from the Bulgarian BEN subjects compared to those from the 
Romanian BEN subjects and included citrate, TMAO and pyruvate.  
From assessment of these changes it appeared that the Romanian BEN subjects were displaying 
urinary changes that would be expected where damage to the tubular function had occurred, probably 
in the cortical region of the kidney. NMR data concerning organic acids is reminiscent of a Warburg 
effect. However, these same effects were not observed in the Bulgarian BEN subjects where the large 
TMAO alteration was observed. TMAO acts as a renal osmolyte and has been suggested to reflect 
alteration in the medulla. Whether these differences imply a different stage of the onset of BEN or a 
variation in the causative mechanism would require further study. Clustering of the Bulgarian BEN 
individual  (Supplementary  Table  2,  case  15)  in  Romanian  BEN  scores  space  (Figures  2  and  3) 
correlates with the NMR data showing organic aciduria, amino aciduria and glucosuria. Toxins 2011, 3                               
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Figure 3. Scores plot of the first two components showing the separation of the samples 
from the Romanian BEN subjects compared to all other groups. 
 
Figure 4. Scores plot of the second and third components with the Romanian BEN samples 
removed from the visualisation showing the clustering each of the other groups. 
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4. Discussion 
Notably,  urines  of  the  three  Romanian  control  subjects  from  hyperendemic  villages  and  which 
clustered towards the well separated BEN group (Figure 2) had low creatinine concentration and the 
group included the person suspected as developing BEN and we recognise possible diagnostic potential. 
Geographical differentiation in expression of BEN, revealed by measurement of urinary biomarkers 
and achieved through access to sophisticated analytical instrumentation, must raise the question of 
aetiology. The present pilot study implies that, if urinary biomarker expression of BEN differs between 
two discrete though adjacent localities in the Balkans, BEN could be a heterogeneous morbidity with 
respect to causal factors. For the present purpose, BEN refers just to the chronic bilateral renal atrophy 
which  has  been  recognised  for  over  half  a  century  as  hyperendemic  in  very  specific  parts  of  the 
Balkans. An assumption is that BEN has homogeneous aetiology across its particular Balkan foci, 
mainly one each in Romania and Bulgaria and several throughout the former Yugoslavia (currently in 
adjacent areas of Croatia and the Republika Srpska region of Bosnia, and in several southern parts of 
Serbia). Although the disease may have similar clinical manifestation as a progressive silent bilateral 
renal atrophy across the region, it may be prudent not to assume aetiological homogeneity. Rather 
frequently BEN is accompanied by transitional cell carcinoma of the upper urinary tract, different in 
type and location from renal cell carcinoma originating in the renal parenchyma. The reverse has not 
been observed. It would be unwise to assume, therefore, that the bilateral renal atrophy and urinary 
tract tumourigenesis are both caused by the same agent; tumourigenesis could be consequent on the 
progressive loss of renal function, occurring during the many years of silent development of BEN. 
Conventional urinalysis routinely used for chemical pathology diagnostic purposes has not revealed 
any biomarkers for the renal atrophy, but the present application of metabolomic methodology opens a 
way to view more sophisticated detail. Already our 
1H NMR spectroscopic data offers new potential, 
and further detail may emerge as our HPLC/MS/MS data is studied. Hence, comparative analysis of the 
difference in composition of urine of Balkan healthy subjects in BEN villages and of those diagnosed 
with BEN by the most modern criteria [9,10], all carefully selected through international co-operation, 
could reveal a new level of diagnostic detail through application of the analytical power of 
1H NMR 
spectroscopic and mass spectrometric methodologies to very small volumes of urine. 
Historically, since BEN was first recognised in Bulgaria [5], several hypotheses were advanced 
from within the Balkans. A poisoning of the water by wartime munitions was thought plausible for 
regions of former conflict in Croatia and Serbia in the 2nd World War. Involvement of the arable weed 
birthwort  (Aristolochia  clematitis)  was  suggested  in  Serbia  because  of  a  somewhat  analogous 
nephropathy  in  horses  [11].  The  biological  activity  of  its  mainly-seedborne  toxin,  aristolochic  
acid (AA), was even recognised on account of clinical trials as a human anti-tumour agent [12]. A viral 
infection  has  been  proposed  [13].  On  account  of  isolation  and  structural  characterisation  of  the 
nephrotoxic  mycotoxin  ochratoxin  A  (OTA)  in South Africa in  the 1960s [14], and its  economic 
impact as the cause of a troublesome nephropathy affecting the Danish bacon industry during mid-20th 
century, this toxin was proposed as the cause also of BEN [15,16]. Concurrently, despite prevailing 
political barriers, UK study of nephrotoxic moulds at the MRC Toxicology Laboratory focused on 
food-spoilage fungi from BEN villages in Bulgaria and Romania. Fungi such as Aspergillus ochraceus 
and Penicillium verrucosum (formerly described as P. viridicatum [17]), expressing biosynthesis of Toxins 2011, 3                               
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OTA,  were  not  apparent.  However,  Bulgarian  isolates  of  a  common  food-spoilage  mould  
(Penicillium verrucosum var. cyclopium) from the Bulgarian nephropathy region near Vratza were 
found to cause striking histopathological changes specifically in rat kidneys when cultured biomass or 
extract was administered per os [18]. The active ingredient(s) was not characterised and long-term 
exposure studies were not made, but potential necrotising and tumourigenic activities were diagnosed 
from the pyknotic and proliferative features. Since then, the topic has been studied further [19–21] but 
the  toxin  structure  remains  elusive.  Extensive  cytogenetic  study  of  BEN  has  continued  in 
Bulgaria [22],  familial  variations  in  lipid  metabolism  have  been  observed  in  well-documented 
hyperendemic populations in Southern Serbia [23], and interesting coincidence of disease patterns with 
superficial lignite coal deposits has raised questions about toxicity of leachate in drinking water [24]. 
In comprehensive metabonomic urinalysis from a 90-day OTA gavage study in rats, based on the 
protocol  of  the  NTP  study  [25],  potentially  nephrocarcinogenic  dose  regimens  (averaging  50  or  
150 µg OTA/kg body weight/day during each week) provided for discrimination of treated animals 
from  controls  [26]  according  to 
1H  NMR  spectroscopy  findings.  However,  no  discrimination  was 
evident at the lowest dose (average 15 µg/kg/day), translating simply to ~1 mg/day for a human adult. 
Since  such  projected  human  exposure  exceeds  by  about  three  orders  of  magnitude  the  exposure 
commonly measured in Balkan environments [27,28], the discriminators identified for higher OTA 
exposure in the rat in chronic [26,29] or acute [30] experiment would hardly be expected to have 
become apparent in BEN patients in the present study. Consequently we find no indicator of significant 
OTA exposure and are not persuaded concerning OTA as an aetiological factor in the bilateral renal 
atrophy of BEN. Similar conclusion has been made from other reasoning [31]. 
With the discovery of its potent nephrocarcinogenicity in male rats [25], OTA became a popular 
etiological candidate for BEN because it can readily be ingested via food spoilage, albeit usually in 
extremely  small  amounts,  and  similarities  were  seen by some researchers with mycotoxic porcine 
nephropathy [15,16]. Increasingly sensitive chromatographic methodology was also revealing OTA 
more widely as a food contaminant but this hardly fits the highly mosaic occurrence of BEN. OTA‘s 
urinary tract carcinogenesis in rodents, targeting renal parenchyma, differs from the transitional cell 
carcinomas often associated with BEN, and the inconvenient disparity between the renal atrophy of 
BEN  and  the  renal  hypertrophy  in  porcine  nephropathy  is  generally  ignored  by  protagonists  of 
ochratoxicosis A as a factor in BEN. However, DNA ploidy distribution in tumours associated with 
BEN matched the marked aneuploidy found in rat renal carcinomas caused by OTA [32], so a role in 
transitional cell tumourigenesis associated with BEN remains a possibility. 
Aristolochic acid then became implicated as an aetiological factor in the so-called Chinese Herbs 
Nephropathy (CHN), recognised in Belgium among women taking a herbal–based slimming regimen 
in the 1990s [33]. Close similarities between CHN and BEN with regard to pathology were described 
by [34] and have focused new attention to a wider concept of AA nephropathy embracing both renal 
fibrosis and urinary tract tumours. A long-term experiment with rabbits given AA (0.1 mg/kg i.p) five 
times each week for 17 or 21 months caused anorexia, marked reduction in weight gain, doubling of 
kidney weight and changes in renal biological data [35]. After the longer period there was notable 
fibrosis in kidneys and two tumours were found, one in kidney and another in a ureter. In rats, a large 
AA dose (50 mg/kg/day for three days) elicited a toxic response [36], but renal function recovered Toxins 2011, 3                               
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within a month. Three renal carcinomas were found after six months, but there were none of the 
transitional cell carcinoma associated with BEN or characteristic of the Belgian CHN.  
Interesting  new  molecular  findings  have  recently  been  published  [37,38]  concerning  defined 
AA/DNA  adducts  isolated  from  urinary  tract  tumours  of  four  Croatian  BEN  cases.  DNA  adduct 
structures matched those associated with TCC tumours of the Belgian CHN. The authors attributed 
both BEN and its associated urinary tract tumours to AA poisoning and this has become a persuasive 
proposition accepted somewhat uncritically [39–41]. Unfortunately, the geographic provenance of the 
analysed tissues was not given, so that it is not possible to estimate the incidence of A. clematitis in the 
environment  of  the  BEN  patients,  relative  to  those  without  BEN,  which  could  have  influenced 
exposure to AA. Notably, chromatographic illustration of adducts showed one tumour to have had 
much greater incidence than the other three, and there is no indication as to whether adducts were in 
tumour parenchyma or were at least partly in nucleated cells of blood in the vascular compartment. To 
assist in confirming any possible causal specificity to the transitional cell carcinomas in some BEN 
patients, it would be good to have seen molecular genetic evidence from tumours in organs other than 
urological ones (e.g., lung) in BEN patients; smoking has been as prevalent in Balkan countries as in 
many other parts of the world. Also, the proposal that AA is an aetiological factor needs to be correlated 
with compelling evidence on natural exposure of individual patients to a carcinogenic dose. A poor fit has 
already been observed [42]. Also a differential exposure pattern must be explained between endemic and 
non-endemic  settings,  considering  the  geographically-unrestricted  distribution  of  the  weed  plant.  In 
strongly promoting AA as the cause of BEN [37], a clear differentiation from OTA was made according 
to genotoxic versus non-genotoxic modes of carcinogenicity, respectively, by selective use of literature. 
However, EFSA took a  more ambivalent  attitude to the  current scientific literature on formation of 
covalent DNA adducts [43] and such a fundamental distinction can not now be sustained [44].  
A  survey  was  conducted  by  Croatian  medical  students  using  a  questionnaire  for  elderly  BEN 
patients with end-stage renal disease supported by haemodialysis at Slavonski Brod, and also to a 
group of apparently healthy residents in the historically-hyperendemic BEN village of Kaniza [45]. 
Whereas agricultural practice and socio-economics differed considerably from 20–30 years previously, 
people  still  recollected  Aristolochia  as  a  weed  in  wheatfields.  Interestingly,  the  BEN  patients 
recollected  more frequent agricultural contamination by  A. clematitis than did healthy residents in 
Kaniza. More details of data collection in the survey would have been helpful in eliminating potential 
bias  in  questioning  patients  with  a  mysterious  terminal  disease  requiring  haemodialysis  for  
life-support, and to acknowledge the challenge of exploring long-retrospective memory. The study 
would  have  benefited  from  more  statistical  power.  It  was  estimated  that  potentially-toxic  historic  
AA-contamination of local wheat flour by A. clematitis seed could have occurred in Croatian endemic 
villages sufficient to match, through bread consumption, the daily 1 mg of AA associated with AA 
nephropathy cases in China. Unfortunately the cited reference for the latter could not be found. Also 
unfortunate  is  the  mis-calculation  [45]  which  underestimated  the  extent  of  Croatian  bread 
contamination  by A. clematitis seeds necessary to match AA intake in Belgian or Chinese human 
nephropathy by a factor of 7.33. 
Consequently, convincing evidence for natural toxigenic intake of AA in the specific nephropathy 
households of Croatian nephropathy villages, such as Kaniza at flood plain level near the Sava river, Toxins 2011, 3                               
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remains to be demonstrated. For this to apply also to the highly mosaic distribution of nephropathy 
households in hyperendemic villages across the several endemic areas in Balkan countries will require 
evidence which accommodates their heterogeneous topography and different agriculture. For example, 
in our experience, the historically hyperendemic Romanian village (Erghevita [46] has a much more 
undulating  topography  than  that  of  Kaniza,  and  A.  clematitis  is  a  common  weed  there.  Notably, 
Figure 5 illustrates in 2004 the extensive infestation in the garden of a household of a recently deceased 
male BEN patient. At first sight, although a striking coincidence, a plausible direct connection between 
plant  and  disease  is  difficult  to  envisage.  The  springtime  infestation  illustrated  could  hardly  have 
persisted to full maturity so close to the house. Dried and powdered leaves are used by some people in 
rural  communities,  mixed  with  pig  fat,  for  topical  application  for  arthritic  pain  or  bruises;  leaf 
decoction (usually one or two leaves boiled in one litre of water) is also used by women for vaginal 
douching. However, such uses would imply very little or insignificant exposure to AA and be hardly 
focal to specific villages. Topical absorption of traces of AA might occur, sufficient to accumulate for 
detection  as  DNA  adducts  in  tumours  where  impaired  capacity  for  DNA  repair could  allow their 
accumulation.  However,  separate  extensive  GC-MS  urinalysis  of  many  samples  from  Romanian 
nephropathy villages by one of us (C.T.) has failed to find any trace of free AA, although spasmodic 
seasonal use of A. clematitis herbal preparations might in part be responsible for the negative results. In 
the situation illustrated in Figure 5, other ways of ingesting traces of AA might be via eggs or meat of 
chickens having seasonal access to seeding plants, but such routes and skin absorption remain to be 
substantiated. Claims of easy natural contamination of harvested wheat by seeds of A. clematitis are not 
assisted by illustration of the very green weed in a field from which the wheat had apparently long 
since  been  harvested  [33].  The  flour-contamination  hypothesis  is  also  contradicted  by  the  hilly 
topography of the endemic, as well as non-endemic, villages in Romania, where wheat cultivation has 
been very limited. Other crop plants, like staple corn (Zea mais), are much more frequently cultivated 
there, but to what extent AA can contaminate the grain and enter the human food chain are open 
questions. Further, medicinal use of A. clematitis has consistently been reported only for Romania, 
although without any significant difference between endemic and non-endemic households.  
A study of use of herbal therapeutic remedies in Romania, focusing at the turn of the millennium on 
the same BEN endemic area as in the present study has concluded that there was no basis for currently 
invoking such practices as contributing a significant human exposure to AA [41]. A slightly higher 
usage by BEN patients was noted but there was no evidence that that rate occurred also before those 
people developed the morbidity. The occurrence of A. clematitis as a weed around some croplands was 
recognised (and of course we have seen that), but there was no evidence that harvested wheat was 
contaminated  by  the  seeds,  nor  that  grain  cleaning  at  mills  would  have  failed  to  remove  such 
contaminants. AA was not found in any human plasma sample, although the limit of detection of the 
HPLC methodology was not stated. However, authors were influenced by the proposal [45] that in a 
Croatian context wheat flour would historically have been contaminated by A. clematitis seeds and that 
this  could  provide  a  significant  intake  of  AA  within  a  major  dietary  component.  Unfortunately, 
although authors were informed of this error in 2007 it does not yet seem to have been corrected in the 
literature. Thus, in [41], authors were inadvertently misled in the extent to which citation of [45] could Toxins 2011, 3                               
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reasonably support their admission that ingestion of a nephrotoxic dose of AA from bread might have 
occurred in Romania in the 20th century.  
Figure 5. Scene at rear of house of former BEN patient in Erghevita, Romania showing  
re-growth of the dominant weed Aristolochia clematitis. May 2004. 
 
Currently, diametrically-opposed published convictions about OTA versus AA as the cause of BEN 
and  associated  TCC  remain  both  philosophically  unsatisfactory  and  unreconciled  [37,38,47,48]. 
Sensational  journalism  [39]  and  uncritical  attention  to  literature  hardly  fosters  calm  and  rational 
consideration of all the complex factors in a disease that remains unexplained. It is important to satisfy 
the necessary evidence base in epidemiology [49]. 
The present study has been by collaborators with extensive experience with BEN in the field, and 
has been made conscious of various causative hypotheses and with minds completely open to new 
ideas, critical appraisal of current theories, and observing and listening to people in villages and clinics. 
Subjects  enduring  terminal  morbidity  deserve  a  fresh  co-operative international  approach to  BEN. 
When the aetiology of BEN and its tumours is satisfactorily explained the facts about causal agent(s) 
and  their  quantitative  exposure  will  be  seen  to  fit  comfortably  with  the  rigorous  metaphysical 
requirements of the classic Koch‘s Postulates in defining a disease determinant. An example of this, 
concerning a natural toxicant and a mysterious morbidity, was the case of proving step by step that 
trace amounts of the lolitrem B metabolite of a cryptic obligate fungal endophyte in grass is the cause 
of ―ryegrass staggers‖ in agricultural ruminants [50].  
Design of this pilot study in 2003/4 was necessarily based on convenience sampling for logistic, 
ethical and economic reasons. However, this did not constrain the intended novel focus, namely to 
apply state-of-art metabolomic techniques to seek biomarkers of disease, but differentiation of BEN 
patients between Romanian and Bulgarian foci was not expected. The findings need confirmation, and 
people who suffer from a disease that has remained idiopathic for more than half a century deserve Toxins 2011, 3                               
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better understanding of the cause(s). Design now of a comprehensive study with the best international 
co-operation supported by Academies of Science and with access to appropriate methodology would 
seem to be justified. 
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